14  The Ethics of Intervening in Ageing

Whether to slow ageing at all is not a question the science of Parts I–IV can answer. The biology supplies the means; the question of whether the means should be deployed, on whom and on what terms, belongs here. The chapter examines the ethical terrain between therapy and enhancement, and follows the question through risk, research, the boundary between germline and soma, and the obligations that bind one longer-lived generation to the next.

The economic frame closed in the previous chapter on a question the frame itself could not answer. Whether a postponed decline is worth having is not the same question as whether it is wise to undertake; the welfare gain measured in trillions of dollars says nothing about whether longer late lives are good lives, nor about whose conception of the good ought to count when the institutions of an ageing world decide what to fund. Ethics enters here as the discipline that takes those questions seriously. The chapter that follows works on four levels at once: at the conceptual level, asking what the distinction between treating disease and enhancing capacity amounts to in a domain where the disease is the universal trajectory of life itself; at the clinical level, asking how informed consent and risk acceptance can mean anything when the consequences of an intervention will be measured in decades; at the level of research practice, asking what laboratory work on embryos, chimeras and the germline can ethically be done in pursuit of a longer life; and at the level of social structure, asking what obligations bind a generation that has access to a postponed decline to the generations that follow. The traditions on which the discussion draws are deliberately several — the normal-function account of disease, the welfarist account of enhancement, the four-principles framework, the prudential-lifespan account of intergenerational equity — because no one of them is adequate to the case at hand, and the disagreements between them are themselves part of the territory to be mapped. A short closing section takes up the edge cases whose value lies in the strain they put on principles that look settled elsewhere, and reserves the deeper question of what ageing and finitude mean for the human condition to the chapter that follows.

A note on the limits of what is attempted here. The aim is not to derive a single normative conclusion from first principles; it is to articulate the structure of the disagreements that any responsible ethics of ageing intervention must navigate. Where the surveyed traditions converge — on the requirement of consent, on the gravity of irreversible interventions, on the unfairness of an unequal distribution of access — those convergences are noted. Where they diverge — on whether ageing is a disease, on whether enhancement is morally distinct from therapy, on whether a slower decline owes anything to those who will not share it — the divergences are described rather than papered over. The reader is owed a clear map rather than a verdict.

14.1 The therapy/enhancement distinction — and the contexts that test it

Whether a geroprotective intervention counts as treatment or as enhancement is a question with serious institutional consequences. Treatment falls within the remit of healthcare systems, attracts insurance reimbursement, qualifies for accelerated regulatory pathways, and inherits the long-standing presumption that medicine acts on illness. Enhancement falls outside it, carries the connotation of consumer choice, and meets a different and largely sceptical regulatory architecture. The institutional consequence is large enough that the conceptual question cannot be left to philosophers alone. The conceptual question is also harder than the institutional one — hard enough that four serious traditions have given four importantly different answers to it.

The first is the normal-function account, due to Christopher Boorse and developed at length by Norman Daniels. On this view, disease is a deviation from species-typical statistical normality in the functioning of a biological system, and the proper task of medicine is to restore that normality where it has been lost (Boorse, 1977; Daniels, 2008). Enhancement, by contrast, takes a person beyond species-typical functioning into a state no biological reference class would call normal. The line between treatment and enhancement on this view is principled rather than arbitrary, anchored in a biological fact about the species. Its difficulty when applied to ageing is immediate: the gradual loss of function with age is itself species-typical, and a strict reading of the account therefore implies that ageing cannot be treated because there is nothing pathological about it. Daniels notes the awkwardness without resolving it. The account fits the polio vaccine cleanly and the postponement of frailty awkwardly.

The second is the welfarist account, articulated most directly by Julian Savulescu and Guy Kahane in their formulation of the Principle of Procreative Beneficence but applicable more widely. On this view, the morally relevant question about any intervention is whether it improves welfare; the distinction between treatment and enhancement is at best descriptive and at worst misleading, because what matters is the welfare gain, not whether the starting point counts as pathological (Savulescu & Kahane, 2009). Applied to ageing, the welfarist view dissolves the conceptual question by refusing to treat it as the right question to ask: if a partial-reprogramming protocol delivers an additional decade of healthy life, the relevant ethics is the ethics of that welfare gain, not the question of whether the starting decline was a disease. The cost of the move is that almost everything becomes potentially permissible if it raises welfare, and the framework must therefore borrow heavily from other principles — autonomy, justice, the prevention of harm — to draw the lines it does not draw itself.

The third is the four-principles framework of Tom Beauchamp and James Childress, the working ethics of most biomedical practice. The framework rests on four mid-level commitments — respect for autonomy, beneficence, non-maleficence and justice — which are taken to be widely shared across moral traditions and to be applied through specification and balancing in particular cases rather than from a single deeper principle (Beauchamp & Childress, 2019). On the treatment/enhancement question the four principles offer no decisive answer, and that is intentional: the framework is procedural rather than substantive, and the merit of an intervention turns on how the four are weighed in the specific case rather than on whether it fits a prior category. For the ethics of ageing interventions the framework’s value is operational: it is the lingua franca of research ethics committees and clinical practice, and any geroprotective trial will be evaluated through it whether or not the deeper conceptual question has been resolved.

The fourth is prudential-lifespan account of Norman Daniels, introduced in the previous chapter in its application to access (Daniels, 2008). Its bearing on the treatment/enhancement question is oblique but important. The account asks how a prudent planner would distribute health goods across the stages of a single life, in ignorance of which stage they would occupy. Applied to ageing interventions, the question becomes whether a prudent planner would judge such interventions to be part of the legitimate task of healthcare. The answer the framework yields depends on the planner’s risk-aversion and their conception of what makes a life go well — on whether they would prefer an evenly extended life of moderate vigour to a sharply terminated one of higher peak — and the framework therefore frames the substantive question without settling it. Its strength is the discipline it imposes on the framing: any case for or against geroprotective intervention must be a case the planner would endorse from behind the veil, not merely from the position of the present older self.

A separate strand of debate has approached the question from the side of nosology — by asking whether ageing should be classified as a disease in the international diagnostic catalogues. The case that it should was made forcefully by Bulterijs and colleagues in 2015, who argued that biological ageing meets every criterion the World Health Organization uses to identify diseases — characteristic diagnostic features, identifiable mechanisms, predictable course and outcomes, known interventions and known genetic and environmental risk factors — and that its omission from the International Classification of Diseases was an artefact of history rather than a defensible conceptual stance (Bulterijs et al., 2015). The argument was extended and operationalised by Khaltourina and colleagues, whose 2020 submission to the ICD-11 Joint Task Force led to the inclusion of an extension code for “ageing-related” (XT9T) in the Causality chapter of the eleventh revision (Khaltourina et al., 2020). The case against has been made on grounds both empirical (that ageing is too heterogeneous a process to satisfy the requirements of a clinical entity) and ethical (that classifying a universal trajectory of life as a disease risks medicalising the whole of late life and stigmatising the older population). The XT9T compromise — ageing as a causal modifier of other diseases rather than as a disease in itself — is a workable institutional position but does not settle the underlying disagreement.

What does the multiplicity of frameworks imply for the practice of ageing intervention? Three working positions seem stable across the disagreement. First, that the conceptual question of whether ageing is a disease is less consequential than it appears, because the practical regulation of geroprotective interventions will turn on consent, risk, evidence and access — questions on which the four traditions agree more than they disagree.1

Second, that the legitimate task of ageing intervention is not the abolition of ageing but the postponement of its disabling consequences, and that this objective can be defended on every framework surveyed: as a restoration of function on the normal-function account (because the function deviating from the relevant reference class is the late-life one); as a welfare gain on the welfarist account; as the prevention of harm and the discharge of beneficence under the four-principles framework; and as the kind of intervention a prudent lifespan planner would consent to. Third, that the distinction between treatment and enhancement, while institutionally consequential, is contextual rather than metaphysical, in a sense the closing observation of this section makes explicit.

Table 14.1 summarises the four traditions on the questions that bear most on ageing.

Table 14.1: Four normative frameworks for assessing intervention in ageing, with the position each takes on disease-status, the location of the therapy/enhancement line, and the regulatory implication. The frameworks disagree on the metaphysics and converge on most of the practical regulation.
Framework What ageing is What counts as enhancement Criterion of acceptance Regulatory implication
Normal-function (Boorse, 1977; Daniels, 2008) Species-typical decline; not a disease in the strict sense Any move beyond species-typical function for the relevant age Restoration of the function deviating from the reference class Geroprotection is treatment for late-life function loss; the line holds
Welfarist (Savulescu & Kahane, 2009) A welfare-reducing state The distinction is descriptive at best, irrelevant at worst Net welfare gain, weighted by autonomy and harm-prevention Treatment/enhancement line is dissolved; case-by-case welfare assessment
Four principles (Beauchamp & Childress, 2019) A clinical fact requiring no prior classification Whatever a particular intervention does beyond a person’s baseline Specification and balancing of autonomy, beneficence, non-maleficence and justice in the case Procedural; permits intervention if the four principles are jointly satisfied
Prudential lifespan (Daniels, 2008) A predictable feature of the life course to be planned for An intervention beyond what a prudent planner would consent to under uncertainty Acceptability from behind the veil of the planner’s life stage Frames the question; the verdict depends on the planner’s risk tolerance and conception of the good
TipA contextual reading of the line

The line between treatment and enhancement is not fixed by biology; it shifts with the environment in which the function is to be exercised. Consider the same neuroprosthesis in two settings. In an Earthbound clinic, an implant that improves spatial orientation beyond the human norm is an enhancement: the user is being given a capacity outside the species-typical range. In a long-duration low-gravity environment, the same implant becomes a piece of life-supporting therapy, because Earth-evolved orientation systems fail there and the device restores a function that the new environment has stripped away (Agar, 2025). The example is artificial today but the moral is not: what we call therapy depends on the environment we treat as the reference, and the reference is itself a normative choice. The deeper point — that an honest ethics of intervention must specify the environment of reference rather than treat it as given — applies as much to the ageing person in a contemporary clinic as to any future astronaut. The development of this line of argument into a wider account of how a humanity transformed by enhancement would relate to its unenhanced ancestors is taken up in the next chapter.

14.3 Chimeras, embryos and the rejuvenation laboratory

Two of the research lines on which the rejuvenation project most directly depends operate in territory that has, for fifty years, been the most heavily regulated in biomedicine: the work with human embryos and the work with chimeric organisms in which human and non-human cells are combined. The first underlies most of what is now known about cellular identity, pluripotency, the Yamanaka reset and the ground zero phenomenon discussed in Chapter 8; the second underlies the regenerative-medicine strategy of growing human-compatible organs in animal hosts, examined in Section 9.4.1. Both are governed by an oversight architecture whose central document is the Guidelines for Stem Cell Research and Clinical Translation maintained by the International Society for Stem Cell Research, last comprehensively revised in 2021 and updated again in 2025 to address stem-cell-based embryo models (Lovell-Badge et al., 2021).

The 2021 guidelines retain, with modifications, the historical 14-day rule: research on human embryos in vitro may proceed up to the formation of the primitive streak or to fourteen days post-fertilisation, whichever comes first. The rule originated as a pragmatic compromise in the early 1980s; it has held for four decades despite the biological case for relaxation that has grown as in-vitro culture systems have extended past two weeks. The 2021 guidelines moved the rule from a categorical prohibition to a category 2 designation requiring specialised review for research that proposes to extend culture past the limit, recognising that the original justification — that the primitive streak marks the earliest possible point of individuation and of nervous-system development — is biologically defensible but not absolute. The principal practical effect has been to permit extended-culture research in jurisdictions that follow the guidelines (notably the United Kingdom, on a case-by-case basis), while preserving the categorical bar in others. The ethics of the move is debated. The case for extension turns on the research value of observing post-implantation development directly rather than inferring it; the case against turns on the absence of any clear successor stopping point once the original is breached.

The work with stem-cell-based embryo models — three-dimensional structures derived from pluripotent cells that mimic features of embryonic development without being embryos in the strict sense — has produced the most consequential update to the framework. The 2025 update of the guidelines treats such models as a distinct research category, requires specialised oversight for those replicating later stages, and prohibits their culture to the point of potential viability or their transfer to any uterus, animal or human (Lovell-Badge et al., 2021). The prohibition is intentionally pre-emptive: the technology is not yet at the point where transfer would be biologically plausible, and the guidelines aim to set the boundary before research practice approaches it. For the rejuvenation field the relevance is direct, because the same pluripotency reset that produces these models is the experimental basis for understanding the embryonic baseline against which partial reprogramming protocols measure their effects.

The chimera question is harder and the oversight architecture less settled. The 2021 guidelines permit, with appropriate oversight, research involving the introduction of human pluripotent cells into non-human animal embryos at the pre-implantation stage, with categorical prohibitions on three specific scenarios: the breeding of chimeric animals in which the human cells have contributed to the germline, the transfer of human-animal chimeric embryos to a human uterus, and the introduction of human pluripotent cells into the embryos of non-human primates beyond strictly limited research contexts. The framework permits the development of human-organ-bearing animals (the pig-grown kidney is the working example) while preventing the development of animals whose moral status would be ambiguous. The critical literature has not been uniformly satisfied. A pointed critique published in Bioethics in 2022 argued that the ISSCR framework minimises moral-status concerns about human-animal brain chimeras to a degree not shared by other major reports on the same question, and that the assumption that such chimeras will not develop higher moral status than ordinary research animals is the empirical question the research is being conducted to investigate, not a premise it can take for granted (2022). The case for some categorical limits on neurological chimerism, the critique argues, is independent of the empirical question of whether any particular experiment will in fact cross them.

A subsidiary research line, less visible in the regulatory architecture but directly bearing on ageing intervention, concerns the use of human embryonic and reprogrammed cells to model age-associated processes. The epigenetic ground zero phenomenon — the observation that biological age, as measured by epigenetic clocks, falls sharply at a defined point in early embryonic development — locates a natural rejuvenation event that experimental work with embryo models can in principle study directly (Kerepesi et al., 2021). The ethical question is whether the research value of such studies justifies the use of human embryonic material that would otherwise be prohibited or constrained. The 2021 ISSCR framework allows the use of supernumerary embryos donated from fertility clinics, with consent, for research of demonstrated scientific value and with specialised oversight; it does not permit the creation of embryos for research purposes alone. The line is the one most consistently maintained across international frameworks, and the ground zero research has so far operated within it.

14.4 Germline and soma: the line that anti-ageing research has not crossed

The other boundary maintained with unusual consistency across the contemporary regulatory architecture is the line between somatic and germline interventions — between changes that affect only the body of the individual treated and changes that affect their gametes and so their descendants. The line has held even under the substantial regulatory pressure created by CRISPR-Cas9 and the Chinese case of 2018 in which He Jiankui reported the birth of edited twins; the international response established a near-universal prohibition on clinical germline editing that has not, at the time of writing, been formally relaxed in any major jurisdiction. The relevance to ageing intervention is that the principal experimental work on rejuvenation — partial reprogramming, senolysis, geroprotector administration — has so far operated entirely on the somatic side of the line, and the prohibition on germline application has not been seriously challenged from within the field.

The ethical case for the boundary has been articulated most carefully in the From Chance to Choice analysis of Buchanan, Brock, Daniels and Wikler, which distinguished germline from somatic interventions not on the grounds that the former are more powerful (they are not necessarily more powerful per individual) but on the grounds that they engage a different set of moral considerations: heritability, the affected future persons who cannot consent, the closure of options for descendants, and the cumulative population-level effect of decisions made one family at a time (Buchanan et al., 2000). The same distinction was reinforced by the analysis of Robert Sparrow, who argued that genome editing’s relation to identity — whether the intervention modifies the same person or brings a different person into existence — turns on whether the intervention occurs before or after the conditions on which identity depends are fixed, and that the answer differs systematically between germline and somatic editing (Sparrow, 2022). The somatic intervention modifies a person; the germline intervention is implicated in the constitution of who that person is. The argument has been challenged from multiple directions in the journal’s open peer commentary, but the basic structural difference between the two types of intervention is not, at the level of moral relevance, in dispute.

The application to ageing has a specific shape. A geroprotective somatic intervention modifies the trajectory of an existing person who can be informed, who can consent, and whose autonomy the intervention is asked to respect. A geroprotective germline intervention — one that, say, edited the genes regulating telomere maintenance or DNA-damage response in gametes or early embryos — would modify the trajectory of an unborn person who cannot consent, whose interest in the modification cannot be determined, and whose descendants would inherit the modification by default. The asymmetry is not absolute (somatic interventions in children also affect persons who cannot fully consent, and the genetic counselling tradition has developed the framework for those cases), but it is wide enough to support the categorical distinction the regulatory architecture has drawn.

The reason this matters for the present field is not that anyone has yet proposed germline interventions for the postponement of ageing. It is that the technologies on which the field depends — CRISPR-Cas9 editing of metabolic and damage-response genes, the experimental rewriting of telomere length, the introduction of trophic factors and rejuvenation transcription factors into early embryos for developmental study — are themselves the technologies on which a future germline application would depend. The field’s current restraint is therefore policy, not capability. Whether it will hold depends on three things: the continued international consensus against clinical germline editing, the absence of a sufficiently compelling near-term therapeutic case to break that consensus, and the maintenance of the institutional infrastructure (the ISSCR guidelines, the national-academy reports, the WHO oversight committee) that has so far kept the question off the active clinical agenda.

A related line of research is making the somatic/germline distinction more porous than it appears, and deserves brief mention. In vitro gametogenesis — the derivation of mature gametes from pluripotent stem cells in culture — has been demonstrated in mice and is under intensive investigation in human cells, with the explicit motivation of extending reproductive lifespan for women whose ovarian reserve has been depleted by chemotherapy, premature menopause or simply by age (Frost & Gilchrist, 2024). Successful human IVG would not be a germline intervention in the sense of editing inherited DNA; it would, however, allow the production of gametes from somatic cells that have themselves been reprogrammed, and would so create a route by which somatic interventions made in late life could enter the reproductive line. The technology is not yet within reach for human use, but the boundary between germline and soma that anti-ageing research has so far respected may not be sustained against it indefinitely. Whether the boundary holds is, again, a question of policy rather than capability.

CautionWhat the boundary has done

The germline/soma boundary has served three functions worth distinguishing. It has limited the propagation of editing errors across generations, so that a mistake made in one individual is contained to that individual. It has preserved the ability of descendants to make their own choices about modifications their ancestors might have made for them. And it has slowed the field enough to allow the institutional infrastructure of oversight to keep up with the technical capability. None of the three functions is dispensable, and all three are eroded simultaneously by any clinical move across the line. The ageing field’s current observance of the boundary is one of the most consequential restraints in contemporary biomedicine.

14.5 Intergenerational and societal justice

The economic chapter introduced the prudential-lifespan account in its application to access, where it framed the question of who should reach geroprotective therapies first as a question about the distribution of health goods across the life course rather than as a contest between age groups. The normative reach of the account is wider than the access question alone, and bears on a series of further problems that the prospect of meaningful intervention in ageing forces into the open. Four of these problems deserve direct treatment. They do not exhaust the ethical territory but they mark its principal contours.

The first is the obligation between a generation that has access to a postponed decline and the generations that do not. If a geroprotective intervention becomes available to a cohort and remains unavailable to its successors — whether because the supply does not scale, because the cost remains prohibitive, or because the regulatory environment in their jurisdiction does not permit access — the first cohort is in a position of unusual moral exposure. The exposure is unusual because the inequality is not, as in other health inequalities, a result of background social conditions that the better-off cohort has only indirectly contributed to; it is a direct consequence of the cohort’s having taken the intervention. The longer-lived generation’s relation to its successors is therefore not the standard intergenerational relation of leaving behind an environment, an economy and a culture. It is the more specific relation of having consumed a finite advantage. The prudential-lifespan view treats this as a constraint on the institutions that govern access: any distribution that the planner would not have consented to from behind the veil is not a distribution the cohort is entitled to enjoy. The constraint is hard to specify and harder to operationalise. It is not optional.

The second is the implication for procreation. The literature on population ethics, most fully developed in Derek Parfit’s Reasons and Persons and the responses it generated, distinguishes between person-affecting views — on which the value of an action depends on its effects on persons who exist or will exist — and impersonal views, on which the value of an action depends on the goodness of the resulting state of affairs whether or not particular persons share in it. The distinction matters here because the choice to have children in a society whose lifespans are being extended is a choice between bringing into existence persons who will themselves be candidates for the extension and persons who will not, depending on when the technology becomes generally accessible. On the person-affecting view, the consideration that bears most directly is the welfare of the prospective child; on the impersonal view, the contribution to the future population’s composition is itself a consideration. Neither view yields a determinate verdict on the procreative implications of geroprotection, and the literature on the question is at best beginning. Two limits are clear. The Savulescu-Kahane Principle of Procreative Beneficence — which requires parents to select, where they have the option, the child with the best expected welfare — does not obviously extend to a recommendation to delay procreation until geroprotective access is improved, because the welfare of the deferred child is not comparable to the welfare of the actual child in the way the principle requires (Savulescu & Kahane, 2009). And the demographic implications of widespread deferral, examined in Section 12.1, are negative enough that any procreative norm shaped by life-extension prospects must be evaluated against the population it would in aggregate produce.

The third is the implication for ageism. The common intuition is that successful geroprotection would reduce ageism by reducing the conditions — frailty, dependence, cognitive decline — that the prejudice attaches itself to. The reverse intuition is at least as defensible. A society in which postponed decline is available to some but not all would acquire a new and visible distinction between the rejuvenated older population and the unrejuvenated older population, and any prejudice currently attached to the latter would, with the institutions of contemporary discrimination, attach itself even more readily to a population now visibly distinguishable from the better-off cohort. The historical analogues — the way in which improved survival from heart disease and cancer in higher-income groups has hardened rather than softened the public’s framing of poorly-controlled chronic disease as a personal failing — should give pause. Geroprotection might reduce ageism, on the right institutional path; on a plausible alternative path it would refine it.

The fourth is the implication for cultural and religious diversity in the conception of a good late life. The traditions of the world do not agree on what constitutes a successful old age, on what is owed to the dying, on whether longer life is a good in itself or a good only when it is good for something. Some traditions place high value on the acceptance of decline as a stage of moral and spiritual development; others on the maintenance of agency for as long as possible; others on the obligations of the young to the old that a shortened decline would alter. The point is not that any one tradition is correct, but that an ethics of ageing intervention that treats the value of postponed decline as self-evident is implicitly choosing one tradition over the others without acknowledging the choice. The prudential-lifespan view yields the same observation in a different vocabulary: the planner behind the veil does not know which conception of the good they will hold, and a distribution of geroprotective access that presupposes any one conception is not a distribution the planner could neutrally consent to. The institutional implication is that consent procedures, public deliberation and the regulatory environment must accommodate genuine pluralism about what postponed decline is good for, rather than treating the good as fixed and the question as one of access alone.

A summary observation closes the section. The four traditions surveyed in §14.1 converge more than they diverge on the question of intergenerational and societal justice: each yields a constraint on the institutions of access, a recognition that the implications of geroprotection extend beyond the individual user, and a requirement that the surrounding society retain the diversity of life-arrangements and life-conceptions that any single intervention risks narrowing (see Han & Magalhães, 2026 for a recent statement of the case in favour). The convergence is striking enough that an ethics of ageing intervention can proceed on it even where the metaphysical disagreements of the first section remain unresolved. What it cannot proceed without is institutional infrastructure adequate to the convergence — the public deliberation, the regulatory architecture, the consent procedures and the access mechanisms that translate principle into practice. That infrastructure is, at present, conspicuously underdeveloped (Partridge et al., 2020).

14.6 Edge cases: from clinical ethics to the human condition

The use of edge cases in ethics is to test principles whose performance at the centre of the domain seems settled. The principles articulated in the preceding sections — the contextual nature of the therapy/enhancement line, the layered structure of consent under uncertainty, the categorical limits on chimeras and germline editing, the convergent constraints on access — were derived from the central cases of contemporary geroscience: the metformin trial, the senolytic protocol, the partial-reprogramming experiment, the long-horizon biomarker study. Each principle has, by design, been formulated to handle those cases. Whether the principles also handle cases at the limit of plausibility is the question that defines the value of an ethical framework, because frameworks that work only at the centre tend to fail abruptly when they are most needed.

The most instructive contemporary edge case has been articulated by Nicholas Agar, whose 2025 Bioethics paper argues that a humanity committed to settlement in space would face conditions under which what is enhancement on Earth becomes therapy in the new environment, and what is moral or prudent restraint on Earth becomes biological obstinacy in deep space (Agar, 2025). The contextual reading of the treatment/enhancement line introduced in §14.1 is the present chapter’s principal use of the argument; the wider claims it generates — about species relativism in the assessment of enhanced human descendants, about the Principle of Humanity that Agar proposes as a check on radical modification, and about what it would mean for the project of being human to admit forms of life that diverge biologically from the Earthbound ancestor population — belong to the philosophical territory of the next chapter and will be taken up there.

What the edge case does for the present chapter is to put two of the framework’s central assumptions under productive strain. The first is the assumption that the environment of reference is stable. The principles of §14.1 treat species-typical function on Earth as the implicit reference against which therapy and enhancement are distinguished. If the relevant environment shifts — through the colonisation case Agar uses, through the long-duration high-altitude or extreme-occupational environments humans already inhabit on Earth, through the contexts of late life that geroprotective intervention itself would alter — the reference must shift with it, and the line moves. The principles survive the shift, but the assumption that the reference is fixed does not. The implication for the regulation of geroprotective intervention is direct: a regulatory architecture that pretends to a fixed reference is regulating a target that the technology is in the process of moving.

The second is the assumption that the international consensus on categorical limits — on chimeras, on germline editing, on cloning — is stable in the face of jurisdictional competition. The history of biomedicine since 1970 contains repeated instances in which national jurisdictions have permitted, on commercial or strategic grounds, research that the international consensus formally prohibits. The plausible near-term version of Agar’s argument is not that humans will need radical enhancement on the Belt; it is that humans seeking to circumvent terrestrial regulation will, well before any genuine space settlement, find jurisdictions in space or in territorially ambiguous environments in which the regulatory architecture surveyed above does not apply. The ethics of ageing intervention is not, on this account, only an ethics for clinics and trials regulated under existing frameworks. It is also an ethics for the next jurisdictional shift, and for the regulatory work that would be required to keep the categorical limits meaningful when the geographies in which they apply are themselves under negotiation.

The closing edge case is the one closest to the central project of the field. The ICD-11 compromise on ageing (the XT9T extension code) is itself an edge case in the sense the section is using: a categorical decision about whether ageing is a disease, taken under institutional pressure, with consequences the framework’s designers could not have fully foreseen (Khaltourina et al., 2020). The compromise functions tolerably at the centre of the domain — it lets clinicians and researchers refer to “ageing-related” conditions without committing the WHO to a position that would medicalise the whole of late life — but its performance at the limits is unstable. A successful geroprotective intervention with broad indications would invite a re-classification debate the compromise was designed to defer. A national jurisdiction that wished to accelerate access could pre-empt the international consensus by reclassifying unilaterally. A pharmaceutical regulator faced with a marketing application for an indication that the compromise does not recognise would have to choose between regulatory creativity and refusal. The institutional architecture that contained the question in the 2010s may not contain it in the 2030s. That is the most consequential edge case of the chapter, because it is the one the field is approaching at the pace of its own progress.

The ethics surveyed in these pages is in a specific sense applied: it begins from the particular interventions, technologies and institutions of the contemporary geroscience programme, and asks how the established traditions of biomedical ethics bear on them. The traditions converge enough to permit a workable framework for clinical practice, research oversight and the politics of access. They do not, however, settle the larger question that runs beneath each of the four levels of the chapter — what it would mean, for the human condition rather than for any particular human life, to take the intervention seriously. Whether ageing has a meaning that postponement would erode, whether finitude is a condition of the kind of life worth living, whether the project of indefinite postponement is a continuation of medicine or a departure from it: those are questions of philosophy rather than applied ethics, and the closing chapter takes them up.

  1. A conversational model could turn the static consent form into a Socratic exchange — walking a participant through concrete scenarios of functional and cognitive decline and making the distant ‘future self’ less abstract. Yet the same fluency makes it the ideal instrument of the dishonest version of that conversation: confident but unfounded risk figures, or reassurance in place of warranted uncertainty. And the decline it anticipates is what erodes the capacity for the recurring re-consent it would serve.↩︎